nadifloxacin

Nadifloxacin (OPC7251) has been used in trials studying the treatment of Acne Vulgaris.

Alalevonadifloxacin is a DNA gyrase and DNA topoisomerase inhibitor and a novel antibacterial compound of the quinolone class targeting MRSa. Alalevonadifloxacin is potentially useful in the treatment of bacterial Gram-positive, Gram-negative and anaerobic infections.

Levonadifloxacin arginine ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. It exhibits antibacterial activity against both methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus. Additionally, it reduces monocyte THP-1 phagocytosis of MRSA and MSSA strains.

Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771), a broad-spectrum anti-staphylococcal agent, exhibits antibacterial activity against both Methicillin-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, effectively reducing these bacteria when phagocytosed by THP-1 monocytes [1].

Levonadifloxacin, a broad-spectrum fluoroquinolone antibiotic, is used potentially for the treatment of staphylococci.

Alalevonadifloxacin HCl is a novel l-alanine ester prodrug of levonadifloxacin.